CA2604640A1 - Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents - Google Patents

Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents Download PDF

Info

Publication number
CA2604640A1
CA2604640A1 CA002604640A CA2604640A CA2604640A1 CA 2604640 A1 CA2604640 A1 CA 2604640A1 CA 002604640 A CA002604640 A CA 002604640A CA 2604640 A CA2604640 A CA 2604640A CA 2604640 A1 CA2604640 A1 CA 2604640A1
Authority
CA
Canada
Prior art keywords
compound
molecular chaperone
substituted
group
nhco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002604640A
Other languages
English (en)
French (fr)
Inventor
Jean-Francois Rossignol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Romark Laboratories LC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2604640A1 publication Critical patent/CA2604640A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA002604640A 2005-04-12 2006-04-12 Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents Abandoned CA2604640A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67022605P 2005-04-12 2005-04-12
US60/670,226 2005-04-12
PCT/US2006/013646 WO2006110814A2 (en) 2005-04-12 2006-04-12 Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents

Publications (1)

Publication Number Publication Date
CA2604640A1 true CA2604640A1 (en) 2006-10-19

Family

ID=36954891

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002604640A Abandoned CA2604640A1 (en) 2005-04-12 2006-04-12 Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents

Country Status (6)

Country Link
US (1) US20070015803A1 (https=)
EP (2) EP1871365A2 (https=)
JP (1) JP2008538362A (https=)
AU (1) AU2006235490A1 (https=)
CA (1) CA2604640A1 (https=)
WO (1) WO2006110814A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2636527C (en) 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
SI2395840T1 (sl) 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem
ES2376931B1 (es) * 2009-04-02 2013-06-25 Universidad Del Pais Vasco Composiciones farmacéuticas para el tratamiento de la metástasis.
ES2425298B1 (es) * 2009-04-02 2014-10-01 Universidad Del País Vasco Composiciones farmacéuticas para el tratamiento de la metástasis
NZ596538A (en) * 2009-05-12 2014-04-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
EP2705155B1 (en) 2011-05-04 2016-04-27 ETH Zurich Rational design of components of the oligo-saccharyltransferase-catalysed asparagine-linked glycosylation
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
PT2546410E (pt) * 2011-07-11 2014-02-17 Omya Int Ag Partículas de carbonato de cálcio hidrofobizado
MX2017006083A (es) 2014-11-11 2017-11-08 Romark Laboratories Lc Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
PT3436074T (pt) * 2016-03-31 2020-08-21 Romark Laboratories Lc Compostos tiazolida para tratamento de infeções virais
US20230303504A1 (en) 2020-07-20 2023-09-28 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
MX2023002208A (es) 2020-08-24 2023-05-17 Romark Laboratories Lc Uso de tiazolidas contra los coronavirus.
KR20230110284A (ko) * 2020-11-17 2023-07-21 장피트 간부전 치료 방법
CN115197164B (zh) * 2021-04-12 2025-04-01 杜心赟 新型噻唑类化合物及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) * 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5532154A (en) * 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5859038A (en) * 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5965590A (en) * 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5856348A (en) * 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6248872B1 (en) * 1996-12-03 2001-06-19 Heska Corporation Parasitic nematode transglutaminase, nucleic acid molecules, and uses thereof
US5935591A (en) * 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US5925622A (en) * 1998-07-13 1999-07-20 Romark Laboratories, L.C. Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6340696B1 (en) * 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US7341717B2 (en) * 2001-04-13 2008-03-11 Gpc Biotech Ag Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor
FR2826018B1 (fr) * 2001-06-18 2005-01-07 Pasteur Institut Tunis Gene associe a la virulence du parasite leishmania
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
CN101010304A (zh) * 2004-09-01 2007-08-01 三菱制药株式会社 分子伴侣功能调节剂
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) * 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
CA2636527C (en) * 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment

Also Published As

Publication number Publication date
US20070015803A1 (en) 2007-01-18
EP2047850A3 (en) 2009-07-29
EP1871365A2 (en) 2008-01-02
JP2008538362A (ja) 2008-10-23
AU2006235490A1 (en) 2006-10-19
WO2006110814A3 (en) 2008-01-31
WO2006110814A2 (en) 2006-10-19
EP2047850A2 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
KR100638684B1 (ko) 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
CN114191552B (zh) 抗新型冠状病毒SARS-CoV-2的药物及其应用
CA2604640A1 (en) Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
WO2019040706A1 (en) COMPOSITIONS AND METHODS FOR TREATING VITILIGO
EA020527B1 (ru) Комбинации ингибиторов вируса гепатита с
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
EP1369119B1 (en) Il-12 expression controlling agents
US20210338648A1 (en) Methods and compositions for reducing serum uric acid
US20230077280A1 (en) Therapeutic compounds for methods of use in insulin resistance
US10413586B2 (en) Antiviral agent comprising recombinant mistletoe lectins
US20230201187A1 (en) Use of nad+ precursors, sting inhibitors, and fxr agonists for inhibiting sars-cov-2 (covid-19)-induced cytokine release
EP3028704A1 (en) Boosting the effect of methotrexate through the combined use with lipophilic statins
DK165966B (da) Forbedret piroxicamholdigt anti-inflammatorisk praeparat
KR20100137442A (ko) 급성 말라리아의 치료를 위한 비스티아졸륨 염 또는 이의 전구체 및 아르테미시닌 또는 이의 유도체의 조합물
BRPI0409790A (pt) 7-azaindóis e seu uso como terapêuticos
KR101086040B1 (ko) 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체
CN118791448B (zh) 一类抗特应性皮炎活性呋喃类化合物、其制备及用途
EP0539180A1 (en) Antiviral agents
CN111329858B (zh) 一种小分子抑制剂在抑制病毒沉默抑制蛋白中的应用
CN113230255A (zh) 阿帕替尼在制备防治nlrp3炎症小体相关疾病的药物中的应用
HK40077547B (zh) 药学组合物及其於治疗肌少症的用途
US20090042901A1 (en) Agent for prevention/therapy of disease caused by keratinocyte growth
US20060257432A1 (en) Pharmaceutical formulations of xanthogenates and inhibitors of viral nucelic acid replication
EA009840B1 (ru) Лечебное средство
UA110965C2 (uk) Застосування 3-(5-аміно-2-метил-4-оксохіназолін-3(4h)-іл)-піперидин-2,6-діону в лікуванні імунних і запальних захворювань

Legal Events

Date Code Title Description
FZDE Discontinued